MGMT启动子甲基化在接受放化疗的新发野生型胶质母细胞瘤患者中的预后作用

目的探求O6-甲基鸟嘌呤DNA甲基转移酶（MGMT）启动子甲基化对新发野生型胶质母细胞瘤（GBM）患者术后预后质量的影响。方法回顾性分析2019年1月—2022年12月在新疆医科大学第一附属医院神经外科新诊断的41例异柠檬酸脱氢酶（IDH）野生型GBM患者的临床资料，通过焦磷酸测序评估GBM患者的MGMT启动子甲基化状态，同时分析与患者预后质量的相关性。结果所有患者的MGMT启动子甲基化发生率为43%。MGMT启动子甲基化的患者中位生存期明显长于未甲基化患者（P<0.05），甲基化患者的总生存期也明显长于未甲基化患者（P<0.05）。结论MGMT启动子甲基化可延长IDH野生型GBM患者术后放化疗后生存期，但未见线性关系，提示MGMT启动子甲基化对预后的影响程度可能不同。

Objective To explore the O6-methylguanine DNA methyltransferase(MGMT) promoter methylation on the quality of postoperative prognosis in patients with new wild-type glioblastoma(GBM). Methods The clinical data of 41 patients with wild-type GBM isocitrate dehydrogenase(IDH) newly diagnosed in Department of Neurosurgery, the First Affiliated Hospital of Xinjiang Medical University from 2019 to 2022 were analyzed retrospectively. MGMT promoter methylation status was assessed in GBM patients by pyrosequencing, while simultaneously analyzed for correlation with patient outcome quality. Results The incidence of MGMT promoter methylation in all patients was 43%. Patients with MGMT methylated promoters had significantly higher median survival than unmethylated patients(P<0.05), and overall survival was significantly longer than unmethylated patients(P<0.05). Conclusion MGMT promoter methylation can prolong the survival after postoperative chemoradiotherapy in patients with IDH wild-type GBM, but no linear relationship is observed, which suggesting that the effect of MGMT promoter methylation on prognosis may be different.